5
Mar
2026
Candid Goes Public, Uniqure’s FDA Dispute, & Moderna’s Big Legal Bill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Mar
2026
Biotech’s Deep Pool of Midsized Companies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Mar
2026
T-cell Engagers for Autoimmune Disease: Ken Song on The Long Run
Ken Song is today’s guest on The Long Run. First things first, this episode was recorded before news broke that Candid Therapeutics went public via a reverse merger with RallyBio. But I must say, that deal was no surprise. Ken was on The Long Run five years ago, in November 2021. At that time, he was CEO of San Diego-based... Read More
26
Feb
2026
Gilead Acquires Arcellx, Alkermes Passes the Torch, Beam Borrows Big
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Feb
2026
Enjoy the Photos: Timmerman Traverse for Damon Runyon Kilimanjaro 2026
One of my favorite Swahili words is “pamoja.” It means together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation concluded on Feb. 16. We had a memorable experience on Kilimanjaro. We did it together. We shared many laughs, and a few tears during our 7-day experience on the highest peak in Africa. This team had some disappointments. Illness and... Read More
19
Feb
2026
FDA Flip-Flops on Flu Vaccine, Compass Passes Phase 3, & J&J Bets on Pennsylvania
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Feb
2026
Discovering Drugs for Cancer and Autoimmunity: Ansu Satpathy
Ansu Satpathy is today’s guest on The Long Run. Ansu is a physician-scientist and an associate professor of pathology and immunology at Stanford University. He’s co-director of the Parker Institute for Cancer Immunotherapy Center at Stanford Medicine, and the co-founder of several startup companies. These include Cartography Biosciences (a cancer drug developer), Santa Ana Bio (a developer of precision autoimmune... Read More
9
Feb
2026
Hike the High Sierras for Damon Runyon Cancer Research
Please join me for a spectacular outdoor experience. It’s the next Timmerman Traverse for Damon Runyon Cancer Research Foundation. This year it will be in the Evolution Range of California’s High Sierras. We will do an extraordinary pair of back-to-back day hikes. We will test our endurance on high-altitude trails, reaching peaks above 13,000 feet. We’ll marvel at breathtaking views... Read More
9
Feb
2026
Gear Check: Timmerman Traverse for Damon Runyon Heads to Kilimanjaro
Gear check is when it starts getting fun and getting real. Our team of 21 hikers has arrived in Tanzania and gotten all our gear sorted. We’ll start the trek on Kilimanjaro Feb. 10. Then we spend the next seven days together on the trails to the top of the highest peak in Africa, elevation 19,341 feet / 5,895 meters.... Read More
5
Feb
2026
Eikon Goes Public, Generate Biomedicines Teed Up, & Sante Reloads
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2026
Eikon IPO on Deck, Biomarin Borrows Big, & Halozyme Rolls with the Surf
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
GSK Scoops Up RAPT, Genentech Bets on NC, & Relief for American Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2026
Helping People Lose Weight and Live Healthy: Ron Renaud on The Long Run
Ron Renaud is today’s guest on The Long Run. He is the CEO of Waltham, Mass.-based Kailera Therapeutics. Kailera is pursuing what could be the biggest opportunity in pharmaceutical industry history. It’s developing a portfolio of GLP-1-based drugs for obesity. Drugs in this category have been around a long time for treatment of Type 2 diabetes, but over the last... Read More
15
Jan
2026
Novo Rolls Out Wegovy Pill, Lilly Acquires Ventyx NLRP3, and Aktis Breaks IPO Ice
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2026
Following the Science to Immunology: Kate Haviland on The Long Run
Kate Haviland is today’s guest on The Long Run. Kate is the former CEO of Cambridge, Mass.-based Blueprint Medicines. Blueprint was one of the big biotech success stories of 2025. The company was acquired by Sanofi for $9.1 billion in cash at closing, and potentially $9.5 billion if certain milestones are met. The company started out with a vision for... Read More
6
Jan
2026
Timmerman Traverse for Damon Runyon Hits $1M Goal, Striving Toward Kilimanjaro
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has done it again. We have exceeded our team goal of raising $1 million for brilliant young cancer researchers around the US. We currently stand at $1,094,672. This team isn’t done. The latest group of 22 biotech executives and investors have one month left before traveling to Tanzania, banding together in common... Read More
6
Jan
2026
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2025
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
11
Dec
2025
5AM, OrbiMed Join $70M Bet on Prolynx Long-Lasting GLP-1 Weight Loss Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.